Wnt Pathway and IL-17: Novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG Axis

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 5, 2010, Pages 369-383

  Daoussis, Dimitrios ^a   Andonopoulos, Andrew P ^a   Liossis, Stamatis Nick C ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bone; IL 17; Joint remodeling; Osteoblastogenesis; Osteoclastogenesis; Rheumatic diseases; Rheumatoid arthritis; Th17; Wnt

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; DISHEVELLED PROTEIN; FRIZZLED PROTEIN; INTERLEUKIN 17; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; WNT PROTEIN;

BONE MASS; BONE REMODELING; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; DRUG TARGETING; GENE MUTATION; HUMAN; JOINT DESTRUCTION; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ANIMALS; BONE REMODELING; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-17; MICE; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RHEUMATIC DISEASES; WNT PROTEINS;

EID: 77949571314     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.10.008     Document Type: Review

References (111)

1. Boyce B.F., Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007, 9(Suppl 1):S1.
2. Schett G., Hayer S., Zwerina J., Redlich K., Smolen J.S. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005, 1:47-54.
3. Johnson M.L., Kamel M.A. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 2007, 19:376-382.
4. Bodine P.V., Komm B.S. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006, 7:33-39.
5. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 2006, 76:103-127.
6. Goldring S.R., Goldring M.B. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007, 13:133-134.
7. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003, 48:594-601.
8. Miller J.R. The Wnts. Genome Biol 2002, 3:3001.
9. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
10. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116:1202-1209.
11. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
12. MacDonald B.T., Joiner D.M., Oyserman S.M., Sharma P., Goldstein S.A., He X., et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007, 41:331-339.
13. Morvan F., Boulukos K., Clement-Lacroix P., Roman R.S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006, 21:934-945.
14. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
15. Lane N.E., Nevitt M.C., Lui L.Y., de Leon P., Corr M. Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007, 56:3319-3325.
16. Daoussis D., Karambetsou M., Solomou E., Bounia K., Tsanaktsi A., Giannopoulos G., et al. Serum Dickkopf-1 (Dkk-1) levels are increased in patients with ankylosing spondylitis. Ann Rheum Dis 2008, 67(Suppl II):383.
17. Daoussis D., Karambetsou M., Solomou E., Tsanaktsi A., Bounia K., Giannopoulos G., et al. Differential response of serum Dickkopf-1 (Dkk-1) levels to anti-TNFα treatment in patients with ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 2008, 67(Suppl II):177.
18. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003, 18:960-974.
19. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 2005, 102:17406-17411.
20. Kulkarni N.H., Onyia J.E., Zeng Q., Tian X., Liu M., Halladay D.L., et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006, 21:910-920.
21. Ezura Y., Nakajima T., Urano T., Sudo Y., Kajita M., Yoshida H., et al. Association of a single-nucleotide variation (A1330V) in the low-density lipoprotein receptor-related protein 5 gene (LRP5) with bone mineral density in adult Japanese women. Bone 2007, 40:997-1005.
22. Hartikka H., Makitie O., Mannikko M., Doria A.S., Daneman A., Cole W.G., et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 2005, 20:783-789.
23. Vestergaard P., Rejnmark L., Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif Tissue Int 2005, 77:1-8.
24. Smith A.J., Gidley J., Sandy J.R., Perry M.J., Elson C.J., Kirwan J.R., et al. Haplotypes of the low-density lipoprotein receptor-related protein 5 (LRP5) gene: are they a risk factor in osteoarthritis?. Osteoarthritis Cartilage 2005, 13:608-613.
25. Urano T., Shiraki M., Narusawa K., Usui T., Sasaki N., Hosoi T., et al. Q89R polymorphism in the LDL receptor-related protein 5 gene is associated with spinal osteoarthritis in postmenopausal Japanese women. Spine 2007, 32:25-29.
26. Bodine P.V., Zhao W., Kharode Y.P., Bex F.J., Lambert A.J., Goad M.B., et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004, 18:1222-1237.
27. Corr M., Lane N.E. FRZB: a bone and joint connection. Arthritis Rheum 2007, 56:3881-3883.
28. Hausler K.D., Horwood N.J., Chuman Y., Fisher J.L., Ellis J., Martin T.J., et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res 2004, 19:1873-1881.
29. Zhu M., Chen M., Zuscik M., Wu Q., Wang Y.J., Rosier R.N., et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum 2008, 58:2053-2064.
30. Lories R.J., Peeters J., Bakker A., Tylzanowski P., Derese I., Schrooten J., et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum 2007, 56:4095-4103.
31. Loughlin J., Dowling B., Chapman K., Marcelline L., Mustafa Z., Southam L., et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci USA 2004, 101:9757-9762.
32. Min J.L., Meulenbelt I., Riyazi N., Kloppenburg M., Houwing-Duistermaat J.J., Seymour A.B., et al. Association of the Frizzled-related protein gene with symptomatic osteoarthritis at multiple sites. Arthritis Rheum 2005, 52:1077-1080.
33. Snelling S., Ferreira A., Loughlin J. Allelic expression analysis suggests that cis-acting polymorphism of FRZB expression does not contribute to osteoarthritis susceptibility. Osteoarthritis Cartilage 2007, 15:90-92.
34. Lane N.E., Lian K., Nevitt M.C., Zmuda J.M., Lui L., Li J., et al. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum 2006, 54:1246-1254.
35. Rodriguez-Lopez J., Pombo-Suarez M., Liz M., Gomez-Reino J.J., Gonzalez A. Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis. Ann Rheum Dis 2007, 66:1052-1055.
36. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
37. Spencer G.J., Utting J.C., Etheridge S.L., Arnett T.R., Genever P.G. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006, 119:1283-1296.
38. Sen M. Wnt signalling in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:708-713.
39. Sen M., Lauterbach K., El Gabalawy H., Firestein G.S., Corr M., Carson D.A. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 2000, 97:2791-2796.
40. Sen M., Chamorro M., Reifert J., Corr M., Carson D.A. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001, 44:772-781.
41. Sen M., Reifert J., Lauterbach K., Wolf V., Rubin J.S., Corr M., et al. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 2002, 46:2867-2877.
42. Nakamura Y., Nawata M., Wakitani S. Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am J Pathol 2005, 167:97-105.
43. Imai K., Morikawa M., D'Armiento J., Matsumoto H., Komiya K., Okada Y. Differential expression of WNTs and FRPs in the synovium of rheumatoid arthritis and osteoarthritis. Biochem Biophys Res Commun 2006, 345:1615-1620.
44. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 2007, 56:2111-2115.
45. Gutcher I., Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007, 117:1119-1127.
46. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
47. Furuzawa-Carballeda J., Vargas-Rojas M.I., Cabral A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007, 6:169-175.
48. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
49. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
50. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
51. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13:711-718.
52. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., Rowan A.D. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002, 61:704-713.
53. Van Bezooijen R.L., Wee-Pals L., Papapoulos S.E., Lowik C.W. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 2002, 61:870-876.
54. Chabaud M., Lubberts E., Joosten L., van Den B.W., Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
55. Chabaud M., Garnero P., Dayer J.M., Guerne P.A., Fossiez F., Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000, 12:1092-1099.
56. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
57. Hirota K., Hashimoto M., Yoshitomi H., Tanaka S., Nomura T., Yamaguchi T., et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204:41-47.
58. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002, 46:802-805.
59. Lubberts E., Joosten L.A., Oppers B., van den B.L., Coenen-de Roo C.J., Kolls J.K., et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
60. Lubberts E., Joosten L.A., van de Loo F.A., Schwarzenberger P., Kolls J., van den Berg W.B. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002, 51:102-104.
61. Lubberts E., van den B.L., Oppers-Walgreen B., Schwarzenberger P., Coenen-de Roo C.J., Kolls J.K., et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003, 170:2655-2662.
62. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
63. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den B.L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
64. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den B.L., Helsen M.M., Di Padova F.E., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005, 167:141-149.
65. Dudler J., Renggli-Zulliger N., Busso N., Lotz M., So A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 2000, 59:529-532.
66. Iwanami K., Matsumoto I., Tanaka-Watanabe Y., Inoue A., Mihara M., Ohsugi Y., et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008, 58:754-763.
67. Joosten L.A., Abdollahi-Roodsaz S., Heuvelmans-Jacobs M., Helsen M.M., van den Bersselaar L.A., Oppers-Walgreen B., et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 2008, 58:98-108.
68. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
69. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
70. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
71. Miranda-Carus M.E., Benito-Miguel M., Balsa A., Cobo-Ibanez T., Perez dA., Pascual-Salcedo D., et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006, 54:1151-1164.
72. Cai L., Yin J.P., Starovasnik M.A., Hogue D.A., Hillan K.J., Mort J.S., et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001, 16:10-21.
73. Kirkham B.W., Lassere M.N., Edmonds J.P., Juhasz K.M., Bird P.A., Lee C.S., et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131.
74. Honorati M.C., Neri S., Cattini L., Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006, 14:345-352.
75. Ryu S., Lee J.H., Kim S.I. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006, 25:16-20.
76. Yamada H., Nakashima Y., Okazaki K., Mawatari T., Fukushi J.I., Kaibara N., et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2007.
77. Daoussis D., Solomou E., Karambetsou M., Bounia K., Tsanaktsi A., Giannopoulos G., et al. Th17 cells are increased in patients with active rheumatoid arthritis. Ann Rheum Dis 2008, 67(Suppl II):152.
78. Agarwal S., Misra R., Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008, 35:515-519.
79. Nistala K., Moncrieffe H., Newton K.R., Varsani H., Hunter P., Wedderburn L.R. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008, 58:875-887.
80. Karim R., Tse G., Putti T., Scolyer R., Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004, 36:120-128.
81. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861.
82. Sato W., Aranami T., Yamamura T. Cutting edge: human Th17 cells are identified as bearing CCR2+CCR5- phenotype. J Immunol 2007, 178:7525-7529.
83. Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007, 56:2936-2946.
84. Li X., Liu P., Liu W., Maye P., Zhang J., Zhang Y., et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005, 37:945-952.
85. Aslan H., Ravid-Amir O., Clancy B.M., Rezvankhah S., Pittman D., Pelled G., et al. Advanced molecular profiling in vivo detects novel function of dickkopf-3 in the regulation of bone formation. J Bone Miner Res 2006, 21:1935-1945.
86. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
87. Ai M., Holmen S.L., Van Hul W., Williams B.O., Warman M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005, 25:4946-4955.
88. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
89. Ai M., Heeger S., Bartels C.F., Schelling D.K. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 2005, 77:741-753.
90. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543.
91. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002, 110:144-152.
92. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750.
93. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005, 8:727-738.
94. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., Macdougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007, 282:14515-14524.
95. Nuttall M.E., Gimble J.M. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004, 4:290-294.
96. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
97. Takada I., Suzawa M., Matsumoto K., Kato S. Suppression of PPAR-γ transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann NY Acad Sci 2007.
98. Pearse R.N. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. Clin Cancer Res 2006, 12:6274s-6278s.
99. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
100. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
101. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
102. Emami K.H., Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett 2007, 253:170-179.
103. Hall C.L., Kang S., MacDougald O.A., Keller E.T. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006, 97:661-672.
104. Ohnaka K., Tanabe M., Kawate H., Nawata H., Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005, 329:177-181.
105. Ohnaka K. [Wnt signaling and glucocorticoid-induced osteoporosis]. Clin Calcium 2006, 16:1812-1816.
106. Wang F.S., Lin C.L., Chen Y.J., Wang C.J., Yang K.D., Huang Y.T., et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 2005, 146:2415-2423.
107. Baron R., Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
108. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol 2006, 16:151-158.
109. Ott S.M. Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab 2005, 90:6741-6743.
110. Robinson J.A., Chatterjee-Kishore M., Yaworsky P.J., Cullen D.M., Zhao W., Li C., et al. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 2006, 281:31720-31728.
111. Robling A.G., Bellido T., Turner C.H. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 2006, 6:354.